arthritis, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, arthritis

A SE, Moses PD, George R 2005 Ocular manifestations of Behcet's disease. Indian Pediatr. 42: 942-945. *
Aarvak T, Chabaud M, Miossec P, Natvig JB 1999 IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J. Immunol. 162: 1246-1251. *
Abad C, Gomariz RP, Waschek JA 2006 Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr. Top. Med. Chem. 6: 151-163.
Abbott JD, Moreland LW 2004 Rheumatoid arthritis: developing pharmacological therapies. Expert Opin. Investig. Drugs 13: 1007-1018.
Abdel-Naser MB, Wollina U, El Hefnawi MA, Habib MA, El Okby M 2006 Non-sarcoidal, non-tuberculoid granuloma in common variable immunodeficiency. J. Drugs Dermatol. 5: 370-372.
Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR 2006 Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 4: 1162-1169.
Abdelouahab N, Heard CM 2008 Dermal and transcutaneous delivery of the major glycoside constituents of Harpagophytum procumbens (devil's claw) in vitro. Planta Med. 74: 527-531.
Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F, van den Berg WB 2008 Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest. 118: 205-216. *
Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, van der Meer JW, Netea MG, van den Berg WB 2007 Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum. 56: 2957-2967. *
Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG 2008 Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 58: 2196-2205. *
Abdulahad WH, Stegeman CA, van der Geld YM, Doornbos-van der Meer B, Limburg PC, Kallenberg CG. 2007 Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 56: 2080-2091. *
Abe M 2006 Complement activation and inflammation. Rinsho Byori 54: 744-756.
Abe T, Takeuchi T 2001 Rheumatoid arthritis and tumor necrosis factor alpha. Autoimmunity 34: 291-303.
Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I 2006 A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J. Rheumatol. 33: 37-44.
Abe Y, Yoshikawa T, Kamada H, Shibata H, Nomura T, Minowa K, Kayamuro H, Katayama K, Miyoshi H, Mukai Y, Yoshioka Y, Nakagawa S, Tsunoda SI, Tsutsumi Y 2008 Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. J. Immunol. Methods 335: 71-78. *
Abebe F, Mustafa T, Nerland AH, Bjune GA 2006 Cytokine profile during latent and slowly progressive primary tuberculosis: a possible role for interleukin-15 in mediating clinical disease. Clin. Exp. Immunol. 143: 180-192. *
Abedin M, Scheurich D, Reimold SC, Reimold AM 2006 Acute coronary syndrome after infliximab infusion. Cardiol. Rev. 14: 50-52.
Abel B, Kurrer M, Shamshiev A, Marty RR, Eriksson U, Gunthert U, Kopf M 2006 The osteopontin - CD44 pathway is superfluous for the development of autoimmune myocarditis. Eur. J. Immunol. 36: 494-499. *
Abeles AM, Marjanovic N, Park J, Attur M, Chan ES, Al-Mussawir H, Dave M, Fisher MC, Stuchin SA, Abramson SB, Pillinger MH 2007 Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: effects of statins and farnesyl and geranylgeranyl transferase inhibitors. Arthritis Rheum. 56: 2840-2853. *
Abeles AM, Pillinger MH 2006 The role of the synovial fibroblast in rheumatoid arthritis - cartilage destruction and the regulation of matrix metalloproteinases. Bull. Hosp. Jt. Dis. 64: 20-24.
Ablassmaier B, Hartmann J 2004 A case of severe gangrenous ischemic colitis following nonsteroidal anti-inflammatory drug intake. Zentralbl. Chir. 129: 510-512.
Ablin JN, Boguslavski V, Aloush V, Elkayam O, Paran D, Caspi D, George J 2006 Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci. 79: 2364-2369. *
Ablin JN, Goldstein Z, Aloush V, Matz H, Elkayam O, Caspi D, Swartzenberg S, George J, Wohl Y 2008 Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis. Rheumatol. Int. Aug 15 [Epub ahead of print]. *
Abou-Raya A, Abou-Raya S 2006 Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun. Rev. 5: 331-337.
Abou-Raya S, Abou-Raya A, Naim A, Abuelkheir H 2007 Chronic inflammatory autoimmune disorders and atherosclerosis. Ann. N. Y. Acad. Sci. 1107: 56-67. *
Abourazzak FE, Guggenbuhl P, Perdriger A, Meadeb J, Gando-Cocley N, Chevrant-Breton J, Hajjaj-Hassouni N, Chales G 2008 Cutaneous lupus induced by etanercept in rheumatoid arthritis. Rev. Med. Interne. 29: 744-747.
Abraham C, Hart J, Locke SM, Baker AL 2008 A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 172-176. *
Abrams B 2005 Long-term sleep apnea as a pathogenic factor for cell-mediated autoimmune disease. Med. Hypotheses 65: 1024-1027.
Abramson SB, Amin A 2002 Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 41: 972-980. *
Abramson SB, Attur M, Yazici Y 2006 Prospects for disease modification in osteoarthritis. Nat. Clin. Pract. Rheumatol. 2: 304-312. *
Abramson SB, Yazici Y 2006 Biologics in development for rheumatoid arthritis: relevance to osteoarthritis. Adv. Drug Deliv. Rev. 58: 212-225. *
Abuzakouk M, Feighery C, Jackson J 2002 Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br. J. Biomed. Sci. 59: 173-179.
Acheson DW 1999 Foodborne infections. Curr. Opin. Gastroenterol. 15: 538.
Ackermann C, Kavanaugh A 2008 Economic burden of psoriatic arthritis. Pharmacoeconomics 26: 121-129.
Ackermann C, Kavanaugh A 2007 Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Targets 11: 1369-1384.
Adachi T, Toishi T, Takashima E, Hara H 2006 Infliximab neutralizes the suppressive effect of TNF-alpha on expression of extracellular-superoxide dismutase in vitro. Biol. Pharm. Bull. 29: 2095-2098. *
Adachi Y, Hinoda Y, Takahashi H, Nakagawa N, Sakamoto H, Itoh F, Endo T, Suzuki S, Imai K 1996 Rheumatoid arthritis associated with ulcerative colitis. J. Gastroenterol. 31: 590-595.
Adachi Y, Yoshio-Hoshino N, Nishimoto N 2008 The blockade of IL-6 signaling in rational drug design. Curr. Pharm. Des. 14: 1217-1224.
Adak M, Gupta JK 2006 Evaluation of anti-inflammatory activity of Calotropis gigantea (AKANDA) in various biological system. Nepal. Med. Coll. J. 8: 156-161.
Adam O 2003 Dietary fatty acids and immune reactions in synovial tissue. Eur. J. Med. Res. 8: 381-387.
Adam O, Beringer C, Kless T, Lemmen C, Adam A, Wiseman M, Adam P, Klimmek R, Forth W 2003 Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. Rheumatol. Int. 23: 27-36. *
Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS 2004 Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J. Am. Acad. Dermatol. 51: 660-662.
Adams KM, Yan Z, Stevens AM, Nelson JL 2007 The changing maternal "self" hypothesis: a mechanism for maternal tolerance of the fetus. Placenta 28: 378-382.
Adarichev VA, Bardos T, Christodoulou S, T Phillips M, Mikecz K, Glant TT 2002 Major histocompatibility complex controls susceptibility and dominant inheritance, but not the severity of the disease in mouse models of rheumatoid arthritis. Immunogenetics 54: 184-192. *
Adarichev VA, Vegvari A, Szabo Z, Kis-Toth K, Mikecz K, Glant TT 2008 Congenic strains displaying similar clinical phenotype of arthritis represent different immunologic models of inflammation. Genes Immun. Jul 24 [Epub ahead of print].
Adarichev VA, Vermes C, Hanyecz A, Ludanyi K, Tunyogi-Csapo M, Finnegan A, Mikecz K, Glant TT 2006 Antigen-induced differential gene expression in lymphocytes and gene expression profile in synovium prior to the onset of arthritis. Autoimmunity 39: 663-673.
Adarichev VA, Vermes C, Hanyecz A, Mikecz K, Bremer EG, Glant TT 2005 Gene expression profiling in murine autoimmune arthritis during the initiation and progression of joint inflammation. Arthritis Res. Ther. 7: R196-R207. *
Adcock I, Evans PC 2007 Resolution of inflammatory responses: a brief introduction. Biochem. Soc. Trans. 35: 261-262. *
Addo A, Le J, Li W, Aksentijevich I, Balow J Jr, Lee A, Gregersen PK, Kastner DL, Remmers EF 2005 Analysis of CARD15/NOD2 haplotypes fails to identify common variants associated with rheumatoid arthritis susceptibility. Scand. J. Rheumatol. 34: 198-203. *
Adebajo AO, Mitchell C 2007 Patient's ethnicity and use of therapies in rheumatoid arthritis. J. Rheumatol. 34: 233.
Adisen E, Karaca F, Gurer MA 2008 When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents. Clin. Exp. Dermatol. 33: 164-166. *
Adlesic M, Verdrengh M, Bokarewa M, Dahlberg L, Foster SJ, Tarkowski A 2007 Histamine in rheumatoid arthritis. Scand. J. Immunol. 65: 530-537. *
Adorini L 2004 Antigen-based immunointervention in human autoimmune diseases. Trends Biotechnol. 22: 547-549. *
Adorini L, Penna G 2008 Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 4: 404-412.
Adriaansen J, Fallaux FJ, de Cortie CJ, Vervoordeldonk MJ, Tak PP 2007 Local delivery of beta interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats. J. Gen. Virol. 88: 1717-1721. *
Adriaansen J, Khoury M, de Cortie CJ, Fallaux FJ, Bigey P, Scherman D, Gould DJ, Chernajovsky Y, Apparailly F, Jorgensen C, Vervoordeldonk MJ, Tak P 2007 Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann. Rheum. Dis. 66: 1143-1150. *
Adriaansen J, Kuhlman RR, Holten JV, Kaynor C, Vervoordeldonk MJ, Tak PP 2006 Intraarticular interferon-beta gene therapy ameliorates adjuvant arthritis in rats. Hum. Gene Ther. 17: 985-996.
Adriaansen J, Tas SW, Klarenbeek PL, Bakker AC, Apparailly F, Firestein GS, Jorgensen C, Vervoordeldonk MJ, Tak PP 2005 Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy. Ann. Rheum. Dis. 64: 1677-1684. *
Adriaansen J, Vervoordeldonk MJ, Tak PP 2006 Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) 45: 656-668. *
Aeberli D, Leech M, Morand EF 2006 Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford) 45: 937-943. *
Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM 2002 Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med. Wkly. 132: 414-422. *
Afif H, Benderdour M, Mfuna-Endam L, Martel-Pelletier J, Pelletier JP, Duval N, Fahmi H 2007 Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is down-regulated by interleukin-1beta in articular chondrocytes. Arthritis Res. Ther. 9: R31. *
Afonso V, Champy R, Mitrovic D, Collin P, Lomri A 2007 Reactive oxygen species and superoxide dismutases: role in joint diseases. Joint Bone Spine 74: 324-329.
Afzali B, Lombardi G, Lechler RI, Lord GM 2007 The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin. Exp. Immunol. 148: 32-46. *
Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, Mischung C, Kusuhara K, Saulsbury FT, Lachmann HJ, Bybee A, McDermott EM, La Regina M, Arostegui JI, Campistol JM, Worthington S, High KP, Molloy MG, Baker N, et al 2003 Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum. 48: 2632-2644. *
Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA, Lachmann HJ, Karenko L, Ranki A, Bakkaloglu A, Besbas N, Topaloglu R, Hoffman HM, Hitman GA, Woo P, McDermott MF 2004 Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun. 5: 289-293. *
Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, Lachmann HJ, Bybee A, Gaudet R, Woo P, Feighery C, Cotter FE, Thome M, Hitman GA, Tschopp J, McDermott MF 2002 Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum. 46: 2445-2452. *
Aganna E, Zeharia A, Hitman GA, Basel-Vanagaite L, Allotey RA, Booth DR, Hawkins PN, Thacker C, Syndercombe-Court D, McDermott MF 2002 An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 46: 245-249. *
Agarwal S, Misra R, Aggarwal A 2008 Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J. Rheumatol. 35: 515-519.
Agarwal SK, Brenner MB 2006 Role of adhesion molecules in synovial inflammation. Curr. Opin. Rheumatol. 18: 268-276.
Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH 2008 Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J. Rheumatol. 35: 1737-1744.
Aggarwal A, Agarwal S, Misra R 2007 Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5(+) and CXCR3(+) CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA). Clin. Exp. Immunol. 148: 515-519. *
Aggarwal BB 2003 Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756. *
Aggarwal BB, Shishodia S 2004 Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. N. Y. Acad. Sci. 1030: 434-441.
Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G, Ichikawa H 2006 TNF blockade: an inflammatory issue. Ernst Schering Res. Found. Workshop 56: 161-186.
Aggarwal P, Aggarwal A, Gupta S, Misra R 2006 Osteopenia is common in adult male patients with active juvenile idiopathic arthritis. J. Rheumatol. 33: 1642-1645.
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL 2003 Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278: 1910-1914. *
Agirbasli M, Inanc N, Baykan OA, Direskeneli H 2006 The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin. Exp. Rheumatol. 24: 580-583.
Agnholt J, Dahlerup JF, Kaltoft K 2003 The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23: 76-85. *
Agrawal C, Raghav SK, Gupta B, Das RH, Chaturvedi VP, Goswami K, Das HR 2005 Tumor necrosis factor-alpha microsatellite polymorphism association with rheumatoid arthritis in Indian patients. Arch. Med. Res. 36: 555-559.
Agrawal S, Misra R, Aggarwal A 2007 Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin. Rheumatol. 26: 201-204. *
Agrawal S, Srivastava R, Sharma B, Pandya S, Misra R, Aggarwal A 2008 IL1RN*2 allele of IL-1receptor antagonist VNTR polymorphism is associated with susceptibility to anklyosing spondylitis in Indian patients. Clin. Rheumatol. 27: 573-576. *
Aguillon G JC, Cruzat C A, Contreras-Levicoy J, Dotte G A, Pesce R B, Aravena MO, Salazar A L, Catalan M D, Abello C P, Aguirre D A, Llanos M C, Cuchacovich TM 2005 Emergent therapies for rheumatoid arthritis. Rev. Med. Chil. 133: 969-976.
Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M 2003 New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies. Rev. Med. Chil. 131: 1445-1453.
Aguillon JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M 2006 Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology 211: 75-84.
Aguillon JC, Cruzat A, Cuenca J, Cuchacovich M 2002 Tumor necrosis factor alpha genetic polymorphism as a risk factor in disease. Rev. Med. Chil. 130: 1043-1050.
Aguirre S, Silber AM, Brito ME, Ribone ME, Lagier CM, Marcipar IS 2006 Design, construction, and evaluation of a specific chimeric antigen to diagnose chagasic infection. J. Clin. Microbiol. 44: 3768-3774. *
Ahlqvist E, Bockermann R, Holmdahl R 2007 Fragmentation of two quantitative trait loci controlling collagen-induced arthritis reveals a new set of interacting subloci. J. Immunol. 178: 3084-3090. *
Ahmad K, Rogers S 2007 Two years of experience with etanercept in recalcitrant psoriasis. Br. J. Dermatol. 156: 1010-1014. *
Ahmad R, Qureshi HY, El Mabrouk M, Sylvester J, Ahmad M Dr, Zafarullah M 2007 Inhibition of interleukin 1-induced matrix metalloproteinase 13 expression in human chondrocytes by interferon gamma. Ann. Rheum. Dis. 66: 782-789. *
Ahmad R, Sylvester J, Zafarullah M 2007 MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation. Cell. Signal. 19: 2549-2557. *
Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP 2003 Mapping the HLA association in Behcet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum. 48: 807-813. *
Ahmad YA, Bruce IN 2001 Genetic epidemiology: systemic lupus erythematosus. Arthritis Res. 3: 331-336. *
Ahmadi K, McCruden AB 2005 Macrophage may responses to androgen via its receptor. Med. Sci. Monit. 12: BR15-BR20. *
Ahmadi S, Powell FC 2005 Pyoderma gangrenosum: uncommon presentations. Clin. Dermatol. 23: 612-620.
Ahmed MM, Berney SM, Wolf RE, Hearth-Holmes M, Hayat S, Mubashir E, Vanderheyde H, Chang WL, King JW 2006 Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am. J. Med. Sci. 331: 252-256.
Ahmed MM, Mubashir E, Wolf RE, Hayat S, Hall V, Shi R, Berney SM 2006 Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis. South. Med. J. 99: 1209-1215.
Ahn KS, Aggarwal BB 2005 Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann. N. Y. Acad. Sci. 1056: 218-233. *
Ahnfelt-Ronne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P 1990 Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 98: 1162-1169.
Ahrens ET, Morel PA 2005 In vivo imaging of autoimmune disease in model systems. Curr. Top. Dev. Biol. 70C: 215-238.
Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ 2007 Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179: 3351-3361. *
Aida Y, Maeno M, Suzuki N, Namba A, Motohashi M, Matsumoto M, Makimura M, Matsumura H 2006 The effect of IL-1beta on the expression of inflammatory cytokines and their receptors in human chondrocytes. Life Sci. 79: 764-771. *
Aiello M, Chetta A, Marangio E, Zompatori M, Olivieri D 2004 Pleural involvement in systemic disorders. Curr. Drug Targets Inflamm. Allergy 3: 441-447.
Aigner E, Schmid I, Osterreicher CH, Zwerina J, Schett G, Strasser M, Niksic F, Hohla F, Ramsauer T, Dorn U, Patsch W, Datz C 2007 Contribution of anti-cyclic citrullinated peptide and rheumatoid factors for the diagnosis of arthropathy in patients with hereditary hemochromatosis. Ann. Rheum. Dis. 66: 1249-1251. *
Aimbire F, Albertini R, Pacheco MT, Castro-Faria-Neto HC, Leonardo PS, Iversen VV, Lopes-Martins RA, Bjordal JM 2006 Low-level laser therapy induces dose-dependent reduction of TNFalpha levels in acute inflammation. Photomed. Laser Surg. 24: 33-37.
Ainola M, Mandelin J, Liljestrom M, Konttinen YT, Salo J 2008 Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. Clin. Exp. Rheumatol. 26: 240-246.
Aithal GP 2007 Dangerous liaisons: drug, host and the environment. J. Hepatol. 46: 995-998. *
Aittoniemi J, Baer M, Soppi E, Vesikari T, Miettinen A 1998 Mannan binding lectin deficiency and concomitant immunodefects. Arch. Dis. Child. 78: 245-248. *
Ajiro J, Narita I, Sato F, Saga D, Hasegawa H, Kuroda T, Nakano M, Gejyo F 2006 SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod. Rheumatol. 16: 294-299. *
Ajuebor MN, Carey JA, Swain MG 2006 CCR5 in T cell-mediated liver diseases: what's going on? J. Immunol. 177: 2039-2045. *
Akabane H, Miyagawa N, Nii H, Inami Y, Togawa M, Tanaka H, Inagaki N, Nagai H 2004 The effect of a newly synthesized indazole compound, TAS-3-124, on experimental autoimmune disease. Biol. Pharm. Bull. 27: 1218-1223. *
Akama H 2007 Antibody to IL-1 or IL-15. Nippon Rinsho 65: 1227-1230.
Akaogi J, Nozaki T, Satoh M, Yamada H 2006 Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr. Metab. Immune Disord. Drug Targets 6: 383-394.
Akaogi J, Yamada H, Kuroda Y, Nacionales DC, Reeves WH, Satoh M 2004 Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production. J. Leukoc. Biol. 76: 227-236. *
Akar N, Hasipek M, Ozturk A, Akar E, Tekin M 2006 Serum amyloid A1 -13 T/C alleles in Turkish familial Mediterranean fever patients with and without amyloidosis. J. Nephrol. 19: 318-321.
Akasaka Y, Abe K, Sato T, Inoue H 2005 Regulation of neurokinin-1 receptor messenger RNA expression in synovial fibroblasts of patients with rheumatoid arthritis. Neuropeptides 39: 467-474. *
Akhavani MA, Larsen H, Paleolog E 2007 Circulating endothelial progenitor cells as a link between synovial vascularity and cardiovascular mortality in rheumatoid arthritis. Scand. J. Rheumatol. 36: 83-90.
Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman ED 2007 Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum. 57: 837-844. *
Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D 2004 The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J. Clin. Invest. 113: 1328-1333. *
Akisu C, Delibas SB, Ozkoc S 2005 Evaluation of three different ELISA kits for the diagnosis of trichinellosis. Mikrobiyol. Bul. 39: 325-331.
Akkad DA, Jagiello P, Szyld P, Goedde R, Wieczorek S, Gross WL, Epplen JT 2006 Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int. J. Immunogenet. 33: 59-61. *
Akkari R, Burbiel JC, Hockemeyer J, Muller CE 2006 Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr. Top. Med. Chem. 6: 1375-1399.
Akkoc N, van der Linden S, Khan MA 2006 Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract. Res. Clin. Rheumatol. 20: 539-557.
Akkurt MO, Bektaser B, Ocguder A, Oguz T, Solak S 2005 An unusual complication of familial Mediterranean fever: protracted arthritis with bilateral coxarthrosis and intraosseous amyloidosis of femoral head. Mod. Rheumatol. 15: 358-360.
Akritidis N, Papadopoulos A, Pappas G 2006 Long-term follow-up of patients with adult-onset Still's disease. Scand. J. Rheumatol. 35: 395-397. *
Aksentijevich I, D Putnam C, Remmers EF, Mueller JL, Le J, Kolodner RD, Moak Z, Chuang M, Austin F, Goldbach-Mansky R, Hoffman HM, Kastner DL 2007 The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 56: 1273-1285. *
Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, Goldbach-Mansky R, Dean J, Athreya B, Reginato AJ, Henrickson M, Pons-Estel B, O'Shea JJ, Kastner DL 2001 The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am. J. Hum. Genet. 69: 301-314. *
Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, Rosenberg HF, Austin F, Remmers EF, Balow JE Jr, Rosenzweig S, Komarow H, Shoham NG, Wood G, Jones J, Mangra N, Carrero H, Adams BS, et al 2002 De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46: 3340-3348. *
Al-Arfaj A 2001 HLA-DR pattern of rheumatoid arthritis in Saudi Arabia. Ann. Saudi Med. 21: 92-93.
Al-Awadhi AM, Hasan EA, Sharma PN, Haider MZ, Al-Saeid K 2007 Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis. Rheumatol. Int. 27: 1119-1123. *
Al-Awadhi AM, Olusi S, Hasan EA, Abdullah A 2008 Frequency of abnormal thyroid function tests in Kuwaiti arabs with autoimmune diseases. Med. Princ. Pract. 17: 61-65.
Al-Awadhi AM, Olusi S, Hasan EA, Abdullah A 2007 Serum concentrations of cardiac troponin-I in patients with rheumatoid arthritis, systemic lupus erythematosus, primary Sjogren's syndrome and Graves' disease. Singapore Med. J. 48: 847-849. *
Al-Awadi A, Olusi SO, Al-Zaid N, Prabha K 1998 Serum B2-microglobulin concentration correlates with urinary concentrations of type 1 collagen cross-linked N-telopeptides and deoxypyridinoline in rheumatoid arthritis. Ann. Saudi Med. 18: 113-116.
Al-Heresh AM, Proctor J, Jones SM, Dixey J, Cox B, Welsh K, McHugh N 2002 Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology (Oxford) 41: 525-530. *
al-Jarallah KF, Singal DP, Buchanan WW 1993 Immunogenetics of psoriatic arthritis. Immunol. Invest. 22: 81-86.
Al-Mayouf SM 2007 Familial arthropathy in Saudi Arabian children: demographic, clinical, and biochemical features. Semin. Arthritis Rheum. 36: 256-261. *
Al-Mayouf SM, Al-Sonbul A, Al Jumaah S, Al-Hemidan A 2006 Sarcoidosis: a delayed or missed diagnosis in children. Ann. Saudi Med. 26: 220-223.
Al-Shukaili AK, Al-Jabri AA 2006 Rheumatoid arthritis, cytokines and hypoxia. What is the link? Saudi Med. J. 27: 1642-1649.
Al-Swailem R, Al-Rayes H, Sobki S, Arfin M, Tariq M 2006 HLA-DRB1 association in Saudi rheumatoid arthritis patients. Rheumatol. Int. 26: 1019-1024. *
Al-Wahadneh AM, Dahabreh MM 2006 Familial mediterranean fever in children: a single centre experience in Jordan. East. Mediterr. Health J. 12: 818-823.
Alamanos Y, Voulgari PV, Drosos AA 2006 Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin. Arthritis Rheum. 36: 182-188. *
Alamanos Y, Voulgari PV, Drosos AA 2008 Incidence and prevalence of psoriatic arthritis: a systematic review. J. Rheumatol. 35: 1354-1358.
Alamoudi OS 2006 Sleep-disordered breathing in patients with acquired retrognathia secondary to rheumatoid arthritis. Med. Sci. Monit. 12: CR530-CR534.
Alansari A, Gul A, Inanc M, Ordi J, Teh LS, Ollier WE, Gonzalez-Gay MA, Hajeer AH 2004 Fc receptor gamma subunit polymorphisms and systemic lupus erythematosus. Saudi Med. J. 25: 1445-1448.
Alarcon GS 2001 Psoriatic arthritis, methotrexate, and liver toxicity. J. Clin. Rheumatol. 7: 213-214.
Alarcon-Riquelme ME 2004 Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus. Arthritis Res. Ther. 6: 169-173. *
Alarcon-Segovia D, Alarcon-Riquelme ME, Cardiel MH, Caeiro F, Massardo L, Villa AR, Pons-Estel BA 2005 Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum. 52: 1138-1147. *
Alavi A, Axford JS 2006 The pivotal nature of sugars in normal physiology and disease. Wien. Med. Wochenschr. 156: 19-33.
Alayli G, Kara N, Tander B, Canturk F, Gunes S, Bagci H 2008 Association of transforming growth factor beta1 gene polymorphism with rheumatoid arthritis in a Turkish population. Joint Bone Spine Aug 5 [Epub ahead of print].
Albani S, Roudier J 1992 Molecular basis for the association between HLA DR4 and rheumatoid arthritis. From the shared epitope hypothesis to a peptidic model of rheumatoid arthritis. Clin. Biochem. 25: 209-212.
Albert D, Clarkin C, Komoroski J, Brensinger CM, Berlin JA 2004 Wegener's granulomatosis: possible role of environmental agents in its pathogenesis. Arthritis Rheum. 51: 656-664. *
Albrecht J, Atzeni F, Baldini C, Bombardieri S, Dalakas MC, Demirkesen C, Yazici H, Mat C, Werth VP, Sarzi-Puttini P 2006 Skin involvement and outcome measures in systemic autoimmune diseases. Clin. Exp. Rheumatol. 24: S52-S59.
Alcorta DA, Barnes DA, Dooley MA, Sullivan P, Jonas B, Liu Y, Lionaki S, Reddy CB, Chin H, Dempsey AA, Jennette JC, Falk RJ 2007 Leukocyte gene expression signatures in antineutrophil cytoplasmic autoantibody and lupus glomerulonephritis. Kidney Int. 72: 853-864.
Alemany-Rodriguez MJ, Aladro Y, Amela-Peris R, Perez-Vieitez MC, Reyes-Yanez MP, Deniz-Naranjo MC, Sanchez-Garcia F 2005 Autoimmune diseases and multiple sclerosis. Rev. Neurol. 40: 594-597.
Alenius GM 2007 Psoriatic arthritis - new insights give new options for treatment. Curr. Med. Chem. 14: 359-366.
Alenius GM, Friberg C, Nilsson S, Wahlstrom J, Dahlqvist SR, Samuelsson L 2004 Analysis of 6 genetic loci for disease susceptibility in psoriatic arthritis. J. Rheumatol. 31: 2230-2235.
Alessandri C, Priori R, Modesti M, Mancini R, Valesini G 2008 The role of anti-cyclic cytrullinate antibodies testing in rheumatoid arthritis. Clin. Rev. Allergy Immunol. 34: 45-49. *
Alessandri C, Sorice M, Bombardieri M, Conigliaro P, Longo A, Garofalo T, Manganelli V, Conti F, Esposti ED, Valesini G 2006 Anti-phospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis. Arthritis Res. Ther. 8: R180. *
Aletaha D, Funovits J, Keystone EC, Smolen JS 2007 Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum. 56: 3226-3235. *
Aletaha D, Smolen J 2005 The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin. Exp. Rheumatol. 23: S100-S108.
Aletaha D, Smolen JS 2006 Remission of rheumatoid arthritis: should we care about definitions? Clin. Exp. Rheumatol. 24: S045-S051. *
Aletaha D, Smolen JS 2006 The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum. Dis. Clin. North Am. 32: 9-44.
Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI 2007 Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet. Disord. 8: 37. *
Alexis AF, Strober BE 2005 Off-label dermatologic uses of anti-TNF-a therapies. J. Cutan. Med. Surg. 9: 296-302.
Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A, Douni E, Blackshear PJ, Kontoyiannis DL, Kollias G 2006 Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur. J. Immunol. 36: 2768-2780. *
Alfadhli A, McDonald J, Feagan B 2005 Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459. *
Alfadhli AA, McDonald JW, Feagan BG 2003 Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459. *
Alfredo CS, Nunes NA, Len CA, Barbosa CM, Terreri MT, Hilario MO 2007 Henoch-Shonlein purpura: recurrence and chronicity. J. Pediatr. (Rio J.) 83: 177-180.
Ali AA, Moatter T, Baig JA, Iqbal A, Hussain A, Iqbal MP 2006 Polymorphism of HLA-DR and HLA-DQ in rheumatoid arthritis patients and clinical response to methotrexate - a hospital-based study. J. Pak. Med. Assoc. 56: 452-456.
Ali M, Manolios N 2005 Proteomics in rheumatology: a new direction for old diseases. Semin. Arthritis Rheum. 35: 67-76. *
Ali Y, Tom BD, Schentag CT, Farewell VT, Gladman DD 2007 Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum. 56: 2708-2714. *
Alizadeh BZ, Valdigem G, Coenen MJ, Zhernakova A, Franke B, Monsuur A, van Riel PL, Barrera P, Radstake TR, Roep BO, Wijmenga C, Koeleman BP 2007 Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis. Hum. Mol. Genet. 16: 2552-2559.
Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A 2007 Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin. Exp. Rheumatol. 25: 60-66.
Allanore Y, Seror R, Chevrot A, Kahan A, Drape JL 2007 Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum. 56: 2747-2754. *
Allegretti M, Moriconi A, Beccari AR, Di Bitondo R, Bizzarri C, Bertini R, Colotta F 2005 Targeting C5a: recent advances in drug discovery. Curr. Med. Chem. 12: 217-236.
Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, McLaren CE, Bahlo M, Nisselle AE, Vulpe CD, Anderson GJ, Southey MC, Giles GG, English DR, Hopper JL, Olynyk JK, Powell LW, Gertig DM 2008 Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358: 221-230. *
Allen RL, Bowness P, McMichael A 1999 The role of HLA-B27 in spondyloarthritis. Immunogenetics 50: 220-227.
Allen RL, Trowsdale J 2004 Recognition of classical and heavy chain forms of HLA-B27 by leukocyte receptors. Curr. Mol. Med. 4: 59-65.
Allen-Brady K, Horne BD, Malhotra A, Teerlink C, Camp NJ, Thomas A 2007 Analysis of high-density single-nucleotide polymorphism data: three novel methods that control for linkage disequilibrium between markers in a linkage analysis. BMC Proc. 1 Suppl. 1: S160. *
Alonso D, Elgart GW, Schachner LA 2003 Blau syndrome: a new kindred. J. Am. Acad. Dermatol. 49: 299-302.
Alonso-Ruiz A, Pijoan JI, Ansuategui E, Calabozo M, Urkaregi A, Quintana A 2008 Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet. Disord. 9: 52. *
Aloush V, Ablin JN, Reitblat T, Caspi D, Elkayam O 2007 Fibromyalgia in women with ankylosing spondylitis. Rheumatol. Int. 27: 865-868. *
Aloysius MM, Kaye PV, Lobo DN 2006 Non-steroidal anti-inflammatory drug (NSAID)-induced colonic strictures and perforation: a case report. Dig. Liver Dis. 38: 276-278.
Alpers DH 2002 The role of nutritional deficiency in the osteopenia and osteoporosis of gastrointestinal diseases. Curr. Opin. Gastroenterol. 18: 203-208.
Alpigiani MG, Haupt R, Parodi S, Calcagno A, Poggi E, Lorini R 2008 Coeliac disease in 108 patients with juvenile idiopathic arthritis: a 13-year follow-up study. Clin. Exp. Rheumatol. 26: 162.
Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D 2008 Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants. J. Clin. Periodontol. 35: 51-57.
Alsaeid K, Alawadhi A, Al-Saeed O, Haider MZ 2006 Human leukocyte antigen DRB1*04 is associated with rheumatoid arthritis in Kuwaiti patients. Joint Bone Spine 73: 62-65.
Alsaeid K, Haider MZ, Ayoub EM 2003 Angiotensin converting enzyme gene insertion-deletion polymorphism is associated with juvenile rheumatoid arthritis. J. Rheumatol. 30: 2705-2709.
Alsaeid K, Haider MZ, Sharma PN, Ayoub EM 2006 The prevalence of human leukocyte antigen (HLA) DR/DQ/DP alleles in Kuwaiti children with oligoarticular juvenile idiopathic arthritis. Rheumatol. Int. 26: 224-228. *
Alsaeid KM, Haider MZ, al-Awadhi AM, Srivastva BS, Ayoub EM 2003 Role of human leukocyte antigen DRB1*0307 and DRB1*0308 in susceptibility to juvenile rheumatoid arthritis. Clin. Exp. Rheumatol. 21: 399-402.
Alsaleh G, Messer L, Semaan N, Boulanger N, Gottenberg JE, Sibilia J, Wachsmann D 2007 BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands. Arthritis Rheum. 56: 3202-3214. *
Alstergren P, Larsson PT, Kopp S 2008 Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis. Scand. J. Rheumatol. 37: 155-157.
Althoff CE, Hermann KG, Braun J, Sieper J 2006 Ankylosing spondylitis - current state of imaging including scoring methods. Z. Rheumatol. 65: 688-699.
Altindag O, Karakoc M, Kocyigit A, Celik H, Soran N 2007 Increased DNA damage and oxidative stress in patients with rheumatoid arthritis. Clin. Biochem. 40: 167-171. *
Altobelli E, Maccarone M, Petrocelli R, Marziliano C, Giannetti A, Peris K, Chimenti S 2007 Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population. BMC Public Health 7: 59. *
Altschuler EL, Kast RE 2004 Bupropion for Blau syndrome. Med. Hypotheses 62: 297-298.
Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda AC, Gonzalez-Amaro R 2006 Regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 27: 110-118.
Alvarez I, Collado J, Daura X, Colome N, Rodriguez-Garcia M, Gallart T, Canals F, Jaraquemada D 2008 The rheumatoid arthritis-associated allele HLA-DR10 (DRB1*1001) shares part of its repertoire with HLA-DR1 (DRB1*0101) and HLA-DR4 (DRB*0401). Arthritis Rheum. 58: 1630-1639. *
Alwawi EA, Mehlis SL, Gordon KB 2008 Treating psoriasis with adalimumab. Ther. Clin. Risk Manag. 4: 345-351.
Amano K 2006 Pulmonary infections in patients with rheumatoid arthritis who have received anti-TNF therapy. Intern. Med. 45: 991-992. *
Amat M, Benjamim CF, Williams LM, Prats N, Terricabras E, Beleta J, Kunkel SL, Godessart N 2006 Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br. J. Pharmacol. 149: 666-575. *
Ambrose NL, O Connell PG 2007 Anti-TNF alpha therapy does not always protect rheumatoid arthritis patients against developing pericarditis. Clin. Exp. Rheumatol. 25: 660.
Amemori S, Iwakiri R, Endo H, Ootani A, Ogata S, Noda T, Tsunada S, Sakata H, Matsunaga H, Mizuguchi M, Ikeda Y, Fujimoto K 2006 Oral dimethyl sulfoxide for systemic amyloid A amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review. J. Gastroenterol. 41: 444-449. *
Amengual O, Atsumi T, Komano Y, Kataoka H, Horita T, Yasuda S, Koike T 2007 A polymorphism in human platelet antigen 6b and risk of thrombocytopenia in patients with systemic lupus erythematosus. Arthritis Rheum. 56: 2803-2805. *
Amer R, Bamonte G, Forrester JV 2007 Resolution of juvenile idiopathic arthritis-associated uveitis after development of common variable immunodeficiency. Eur. J. Ophthalmol. 17: 666-668.
American Academy of Family Physicians 2005 Information from your family doctor. Rheumatoid arthritis: what you should know. Am. Fam. Physician 72: 1049-1050.
Amezcua-Guerra LM, Hernandez-Martinez B, Pineda C, Bojalil R 2006 Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis. Gut 55: 1059-1060. *
Amezcua-Guerra LM, Prieto P, Bojalil R, Pineda C, Amigo MC 2006 Microscopic polyangiitis associated with primary biliary cirrhosis: a causal or casual association? J. Rheumatol. 33: 2351-2353.
Amezcua-Guerra LM, Springall R, Marquez-Velasco R, Gomez-Garcia L, Vargas A, Bojalil R 2006 Presence of antibodies against cyclic citrullinated peptides (anti-CCP) in patients with rhupus: a cross-sectional study. Arthritis Res. Ther. 8: R144. *
Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB 1996 A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc. Natl. Acad. Sci. U.S.A. 93: 14014-14019. *
Amin EA, Welsh WJ 2006 A preliminary in silico lead series of 2-phthalimidinoglutaric acid analogues designed as MMP-3 inhibitors. J. Chem. Inf. Model. 46: 2104-2109. *
Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, Koch AE 2007 Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum. 56: 1787-1797. *
Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A 2004 SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford) 43: 658-661. *
Amital H, Barak V, Winkler RE, Rubinow A 2007 Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. Ann. N. Y. Acad. Sci. 1110: 649-660. *
Amital H, Gershwin EM, Shoenfeld Y 2006 Reshaping the mosaic of autoimmunity. Semin. Arthritis Rheum. 35: 341-343. *
Amital H, Govoni M, Maya R, Meroni PL, Ori B, Shoenfeld Y, Tincani A, Trotta F, Sarzi-Puttini P, Atzeni F 2008 Role of infectious agents in systemic rheumatic diseases. Clin. Exp. Rheumatol. 26: S27-S32.
Amlong CA, Nardelli DT, Peterson SH, Warner TF, Callister SM, Schell RF 2006 Anti-interleukin-15 prevents arthritis in Borrelia-vaccinated and -infected mice. Clin. Vaccine Immunol. 13: 289-296. *
Ammon HP 2006 Boswellic acids in chronic inflammatory diseases. Planta Med. 72: 1100-1116.
Amoroso P, Vergani D, Wojcicka BM, McFarlane IG, Eddleston AL, Tee DE, Williams R 1980 Identification of biliary antigens in circulating immune complexes in primary biliary cirrhosis. Clin. Exp. Immunol. 42: 95-98. *
Amos CI, Chen WV, Lee A, Li W, Kern M, Lundsten R, Batliwalla F, Wener M, Remmers E, Kastner DA, Criswell LA, Seldin MF, Gregersen PK 2006 High-density SNP analysis of 642 Caucasian families with rheumatoid arthritis identifies two new linkage regions on 11p12 and 2q33. Genes Immun. 7: 277-286. *
Amos CI, Chen WV, Remmers E, Siminovitch KA, Seldin MF, Criswell LA, Lee AT, John S, Shephard ND, Worthington J, Cornelis F, Plenge RM, Begovich AB, Dyer TD, Kastner DL, Gregersen PK 2007 Data for Genetic Analysis Workshop (GAW) 15 Problem 2, genetic causes of rheumatoid arthritis and associated traits. BMC Proc. 1 Suppl. 1: S3. *
Amoura Z, Dode C, Hue S, Caillat-Zucman S, Bahram S, Delpech M, Grateau G, Wechsler B, Piette JC 2005 Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease. Arthritis Rheum. 52: 608-611. *
Amria S, Hajiaghamohseni LM, Harbeson C, Zhao D, Goldstein O, Blum JS, Haque A 2008 HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition. Eur. J. Immunol. 38: 1961-1970. *
Amu S, Stromberg K, Bokarewa M, Tarkowski A, Brisslert M 2007 CD25-expressing B-lymphocytes in Rheumatic Diseases. Scand. J. Immunol. 65: 182-191. *
Amu S, Tarkowski A, Dorner T, Bokarewa M, Brisslert M 2007 The human immunomodulatory CD25(+) B cell population belongs to the memory B cell pool. Scand. J. Immunol. 66: 77-86. *
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB 2007 Bioavailability of curcumin: problems and promises. Mol. Pharm. 4: 807-818. *
Anandarajah AP, Schwarz EM 2006 Anti-RANKL therapy for inflammatory bone disorders: mechanisms and potential clinical applications. J. Cell. Biochem. 97: 226-232. *
Anaya JM, Correa PA, Mantilla RD, Arcos-Burgos M 2002 TAP, HLA-DQB1, and HLA-DRB1 polymorphism in Colombian patients with primary Sjogren's syndrome. Semin. Arthritis Rheum. 31: 396-405. *
Anaya JM, Correa PA, Mantilla RD, Arcos-Burgos M 2002 Rheumatoid arthritis association in Colombian population is restricted to HLA-DRB1*04 QRRAA alleles. Genes Immun. 3: 56-58. *
Anaya JM, Correa PA, Mantilla RD, Jimenez F, Kuffner T, McNicholl JM 2001 Rheumatoid arthritis in African Colombians from Quibdo. Semin. Arthritis Rheum. 31: 191-198. *
Anaya JM, Mantilla RD, Correa PA 2005 Immunogenetics of primary Sjogren's syndrome in Colombians. Semin. Arthritis Rheum. 34: 735-743. *
Anaya JM, Tobon GJ, Vega P, Castiblanco J 2006 Autoimmune disease aggregation in families with primary Sjogren's syndrome. J. Rheumatol. 33: 2227-2234.
Anders HJ, Zecher D, Pawar RD, Patole PS 2005 Molecular mechanisms of autoimmunity triggered by microbial infection. Arthritis Res. Ther. 7: 215-224. *
Anderson DW 2001 Cytokines as drug targets. IDrugs 4: 375-377.
Anderson GM, Nakada MT, DeWitte M 2004 Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 4: 314-320.
Anderson P, Phillips K, Stoecklin G, Kedersha N 2004 Post-transcriptional regulation of proinflammatory proteins. J. Leukoc. Biol. 76: 42-47. *
Andersson A, Kokkola R, Wefer J, Erlandsson-Harris H, Harris RA 2004 Differential macrophage expression of IL-12 and IL-23 upon innate immune activation defines rat autoimmune susceptibility. J. Leukoc. Biol. 76: 1118-1124. *
Andersson AK, Feldmann M, Brennan FM 2008 Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand. J. Immunol. 68: 103-111. *
Andersson AK, Li C, Brennan FM 2008 Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res. Ther. 10: 204.
Andersson EC, Svendsen P, Svejgaard A, Holmdahl R, Fugger L 2000 A molecule basis for the HLA association in rheumatoid arthritis. Rev. Immunogenet. 2: 81-87.
Andersson IE, Dzhambazov B, Holmdahl R, Linusson A, Kihlberg J 2007 Probing molecular interactions within class II MHC A(q)/glycopeptide/T-cell receptor complexes associated with collagen-induced arthritis. J. Med. Chem. 50: 5627-5643. *
Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O'Shea JJ, Shevach EM 2008 CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J. Exp. Med. 205: 1975-1981. *
Andersson M, Svenungsson E, Khademi M, Lampa J, Brundin L, Wallstrom E 2006 No signs of immunoactivation in the cerebrospinal fluid during treatment with infliximab. Ann. Rheum. Dis. 65: 1237-1240. *
Andersson ML, Petersson IF, Karlsson K, Jonsson NE, Mansson B, Heinegard D, Saxne T 2006 Diurnal variation in serum levels of cartilage oligomeric matrix protein (COMP) in individuals with knee osteoarthritis or rheumatoid arthritis. Ann. Rheum. Dis. 65: 1490-1494. *
Andersson U, Erlandsson-Harris H 2004 HMGB1 is a potent trigger of arthritis. J. Intern. Med. 255: 344-350. *
Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ 2002 HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72: 1084-1091. *
Andersson U, Tracey KJ 2003 HMGB1 in sepsis. Scand. J. Infect. Dis. 35: 577-584.
Andersson U, Tracey KJ 2004 HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum. Dis. Clin. North Am. 30: 627-637, xi.
Andersson UG, Tracey KJ 2004 HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J. Intern. Med. 255: 318-319. *
Andonopoulos AP, Skopouli FN, Dimou GS, Drosos AA, Moutsopoulos HM 1990 Sjogren's syndrome in systemic lupus erythematosus. J. Rheumatol. 17: 201-204.
Andrade RM, Alarcon GS, Fernandez M, Apte M, Vila LM, Reveille JD 2007 Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis Rheum. 56: 622-630. *
Andreakos E 2004 Common and uncommon features of rheumatoid arthritis and chronic obstructive pulmonary disease: clues to a future therapy. Curr. Drug Targets Immune Endocr. Metabol. Disord. 4: 85-92.
Andreakos E, Foxwell B, Feldmann M 2004 Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol. Rev. 202: 250-265. *
Andreakos E, Sacre S, Foxwell BM, Feldmann M 2005 The Toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis. Front. Biosci. 10: 2478-2488.
Andreas K, Luebke C, Haeupl T, Dehne T, Morawietz L, Ringe J, Kaps C, Sittinger M 2008 Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res. Ther. 10: R9. *
Andreev OA, Dupuy AD, Segala M, Sandugu S, Serra DA, Chichester CO, Engelman DM, Reshetnyak YK 2007 Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo. Proc. Natl. Acad. Sci. U.S.A. 104: 7893-7898. *
Andren M, Johanneson B, Alarcon-Riquelme ME, Kleinau S 2005 IgG Fc receptor polymorphisms and association with autoimmune disease. Eur. J. Immunol. 35: 3020-3029. *
Andreoli L, Malacarne F, Ceribelli A, Kutschera I, Tincani A 2007 Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits. Ann. N. Y. Acad. Sci. 1109: 531-537.
Andus T, Stange EF, Hoffler D, Keller-Stanislawski B 2003 Suspected cases of severe side effects after infliximab (Remicade) in Germany. Med. Klin. (Munich) 98: 429-436.
Ang HT, Helfgott S 2003 Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J. Rheumatol. 30: 2315-2318.
Angotti C 2005 Arthritis and skin disease. Skinmed. 4: 293-297.
Angulo JM, Sigal LH, Espinoza LR 1998 Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Semin. Arthritis Rheum. 28: 187-192. *
Angyal A, Prechl J, Sarmay G 2007 Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases. Expert Opin. Biol. Ther. 7: 691-704.
Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, Miller CH, Dutcher PO, Hadley JA, Sanz I 2008 Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J. Immunol. 180: 688-692.
Anshu A, Chee SP 2007 Posterior scleritis and its association with HLA B27 haplotype. Ophthalmologica 221: 275-278.
Antonelli A, Ferri C, Galeazzi M, Giannitti C, Manno D, Mieli-Vergani G, Menegatti E, Olivieri I, Puoti M, Palazzi C, Roccatello D, Vergani D, Sarzi-Puttini P, Atzeni F 2008 HCV infection: pathogenesis, clinical manifestations and therapy. Clin. Exp. Rheumatol. 26: S39-S47.
Antonelli A, Sedie AD, Fallahi P, Ferrari SM, Maccheroni M, Ferrannini E, Bombardieri S, Riente L 2006 High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis. J. Rheumatol. 33: 2026-2028.
Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J 2005 Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52: 1227-1236. *
Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS 2008 Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). J. Rheumatol. 35: 869-876.
Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, Boumpas DT 2007 Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin. Exp. Rheumatol. 25: 23-28.
Antoniu SA 2007 Treatment options for refractory Wegener's granulomatosis: a role for rituximab? Curr. Opin. Investig. Drugs 8: 927-932.
Antoniu SA 2006 Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting? Expert Opin. Investig. Drugs 15: 181-184.
Antoniv TT, Ivashkiv LB 2006 Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 54: 2711-2721. *
Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P 2006 Antibodies to viral citrullinated peptide in rheumatoid arthritis. J. Rheumatol. 33: 647-651.
Anzilotti C, Riente L, Pratesi F, Chimenti D, Sedie AD, Bombardieri S, Migliorini P 2007 IgG, IgA, IgM antibodies to a viral citrullinated peptide in patients affected by rheumatoid arthritis, chronic arthritides and connective tissue disorders. Rheumatology (Oxford) 46: 1579-1582.
Apan TZ, Gursel R, Dolgun A 2007 Increased seropositivity of Helicobacter pylori cytotoxin-associated gene-A in Behcet's disease. Clin. Rheumatol. 26: 885-889. *
Appel H, Kuon W, Kuhne M, Wu P, Kuhlmann S, Kollnberger S, Thiel A, Bowness P, Sieper J 2004 Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis. Arthritis Res. Ther. 6: R521-R534. *
Arai A, Kitano A, Sawabe E, Kanegane H, Miyawaki T, Miura O 2007 Relapsing Campylobacter coli bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia. Intern. Med. 46: 605-609. *
Araico A, Terencio MC, Alcaraz MJ, Dominguez JN, Leon C, Ferrandiz ML 2007 Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2/5-lipoxygenase inhibitor. Life Sci. 80: 2108-2117. *
Arakaki O, Yamamoto Y, Awazawa R, Nonaka K, Taira K, Asato Y, Hagiwara K, Oyama B, Ishii N, Hashimoto T, Uezato H 2008 Case of linear immunoglobulin A bullous dermatosis associated with acquired hemophilia. J. Dermatol. 35: 437-446.
Araujo EP, De Souza CT, Ueno M, Cintra DE, Bertolo MB, Carvalheira JB, Saad MJ, Velloso LA 2007 Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 148: 5991-5997. *
Arbour L, Rupps R, Field L, Ross P, Erikson A, Henderson H, Hill W, Yoshida E 2005 Characteristics of primary biliary cirrhosis in British Columbia's First Nations population. Can. J. Gastroenterol. 19: 305-310.
Archer JR 1981 Search for cross-reactivity between HLA B27 and Klebsiella pneumoniae. Ann. Rheum. Dis. 40: 400-403. *
Ardoin SP, Pisetsky DS 2008 The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation. Mod. Rheumatol. 18: 319-326. *
Arend SM, Breedveld FC, van Dissel JT 2003 TNF-alpha blockade and tuberculosis: better look before you leap. Neth. J. Med. 61: 111-119. *
Arend WP 2002 The mode of action of cytokine inhibitors. J. Rheumatol. Suppl. 65: 16-21.
Aries PM, Witte T, Lamprecht P 2007 Report on the 34th Meeting of the German Clinical Immunology Workgroup, Frankfurt, 03.-04.11.2006. Z. Rheumatol. 66: 63-64.
Arii K, Kumon Y, Sugahara K, Nakatani K, Ikeda Y, Suehiro T, Hashimoto K 2008 Edaravone inhibits collagen-induced arthritis possibly through suppression of nuclear factor-kappa B. Mol. Immunol. 45: 463-469. *
Aringer M, Graninger WB, Steiner G, Smolen JS 2004 Safety and efficacy of tumor necrosis factor blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 50: 3161-3169. *
Aringer M, Smolen JS 2008 The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res. Ther. 10: 202.
Aringer M, Smolen JS 2008 Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin. Drug Saf. 7: 411-419.
Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS 2007 Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 56: 274-279. *
Aristodemou P, Stanford M 2006 Therapy insight: the recognition and treatment of retinal manifestations of systemic vasculitis. Nat. Clin. Pract. Rheumatol. 2: 443-451. *
Arita K, Shimizu T, Hashimoto H, Hidaka Y, Yamada M, Sato M 2006 Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. Proc. Natl. Acad. Sci. U.S.A. 103: 5291-5396. *
Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH 1998 Omega-3 fatty acids in rheumatoid arthritis: an overview. Semin. Arthritis Rheum. 27: 366-370.
Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, Rodriguez-Arboleya L, Navarro-Compan V, Toyos J 2007 Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 46: 529-532. *
Arkfeld DG 2008 The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol. Int. 28: 205-215. *
Arlestig L, Wallberg Jonsson S, Stegmayr B, Rantapaa-Dahlqvist S 2007 Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 25: 866-871.
Armagan O, Ekim A, Dinc A, Oner C 2007 Ankylosing spondylitis in a patient with Turner syndrome: a case report. Rheumatol. Int. 27: 1177-1180. *
Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G 2008 Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J. Exp. Med. 205: 331-337. *
Arman A, Yilmaz B, Coker A, Inanc N, Direskeneli H 2006 Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24: 643-648.
Arnett FC, Hamilton RG, Reveille JD, Bias WB, Harley JB, Reichlin M 1989 Genetic studies of Ro (SS-A) and La (SS-B) autoantibodies in families with systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum. 32: 413-419.
Arnett HA, Viney JL 2007 Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic. Adv. Drug Deliv. Rev. 59: 1084-1092.
Arnold JN, Dwek RA, Rudd PM, Sim RB 2006 Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol. Lett. 106: 103-110.
Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA 2007 The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25: 21-50.
Arostegui JI, Aldea A, Modesto C, Rua MJ, Arguelles F, Gonzalez-Ensenat MA, Ramos E, Rius J, Plaza S, Vives J, Yague J 2004 Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum. 50: 4045-4050. *
Arostegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P, Garcia-Consuegra J, Naranjo A, Ramos E, de Paz P, Rius J, Plaza S, Yague J 2007 NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 56: 3805-3813. *
Arostegui JI, Yague J 2008 Hereditary systemic autoinflammatory diseases. Part II: cryopyrin-associated periodic syndromes, pediatric systemic granulomatosis and PAPA syndrome. Med. Clin. (Barc.) 130: 429-438.
Arrington JL, McMurray DN, Switzer KC, Fan YY, Chapkin RS 2001 Docosahexaenoic acid suppresses function of the CD28 costimulatory membrane receptor in primary murine and Jurkat T cells. J. Nutr. 131: 1147-1153. *
Artlett CM, O'Hanlon TP, Lopez AM, Song YW, Miller FW, Rider LG 2003 HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis Rheum. 48: 2567-2572. *
Arundel C, Lewis JH 2007 Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254.
Arvidson NG, Larsen A, Aaseth J, Larsson A 2007 Short-term effects of the TNFalpha antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis. Scand. J. Clin. Lab. Invest. 67: 337-342. *
Asada Y, Isomoto H, Shikuwa S, Wen CY, Fukuda E, Miyazato M, Okamoto K, Nakamura T, Nishiyama H, Mizuta Y, Migita K, Ito M, Kohno S 2006 Development of ulcerative colitis during the course of rheumatoid arthritis: association with selective IgA deficiency. World J. Gastroenterol. 12: 5240-5243. *
Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi H 2008 Cathepsin K-dependent Toll-like receptor 9 signaling revealed in experimental arthritis. Science 319: 624-627. *
Asarch A, Barak O, Loo DS, Gottlieb AB 2008 Th17 cells: a new therapeutic target in inflammatory dermatoses. J. Dermatolog. Treat. Jul 14 [Epub ahead of print].
Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H, Tamaki K 2006 Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br. J. Dermatol. 155: 330-336. *
Aseni P, Di Sandro S, Mihaylov P, Lamperti L, De Carlis LG 2008 Atypical presentation of pioderma gangrenosum complicating ulcerative colitis: rapid disappearance with methylprednisolone. World J. Gastroenterol. 14: 5471-5473.
Ashino T, Arima Y, Shioda S, Iwakura Y, Numazawa S, Yoshida T 2007 Effect of interleukin-6 neutralization on CYP3A11 and metallothionein-1/2 expressions in arthritic mouse liver. Eur. J. Pharmacol. 558: 199-207. *
Ashok D, Dubey S, Tomlinson I 2008 C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin. Rheumatol. 27: 261-264. *
Ashok D, Kiely P 2007 Bowel associated dermatosis - arthritis syndrome: a case report. J. Med. Case Reports 1: 81. *
Askling J, Bongartz T 2008 Malignancy and biologic therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20: 334-339.
Askling J, Dixon W 2008 The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20: 138-144.
Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A 2008 Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine. Clin. Rheumatol. 27: 377-380. *
Asquith DL, McInnes IB 2007 Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 246-251.
Assi LK, Wong SH, Ludwig A, Raza K, Gordon C, Salmon M, Lord JM, Scheel-Toellner D 2007 Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum. 56: 1776-1786. *
Assous N, Gossec L, Dieude P, Meyer O, Dougados M, Kahan A, Allanore Y 2008 Rituximab therapy in rheumatoid arthritis in daily practice. J. Rheumatol. 35: 31-34.
Astorga G, Cubillos A, Masson L, Silva JJ 1991 Active rheumatoid arthritis: effect of dietary supplementation with omega-3 oils. A controlled double-blind trial. Rev. Med. Chil. 119: 267-272.
Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, Sieper J 2005 HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum. 52: 892-901. *
Atchia II, Kidd CE, Bell RW 2006 Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J. Clin. Rheumatol. 12: 291-293.
Ates A, Karaaslan Y, Aksaray S 2007 Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin. Rheumatol. 26: 499-504. *
Ates A, Kinikli G, Turgay M, Akay G, Tokgoz G 2007 Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: a comparative study. Clin. Rheumatol. 26: 538-545. *
Ates A, Kinikli G, Turgay M, Duman M 2004 The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis. Clin. Rheumatol. 23: 421-425. *
Ates A, Turkcapar N, Olmez U, Tiryaki O, Duzgun N, Uguz E, Duman M 2007 Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers. Rheumatol. Int. 27: 715-722. *
Ates O, Hatemi G, Hamuryudan V, Topal-Sarikaya A 2008 Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients. Clin. Rheumatol. 27: 1243-1248. *
Atkinson TP, Balish MF, Waites KB 2008 Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol. Rev. Aug 27 [Epub ahead of print]. *
Atouf O, Benbouazza K, Brick C, Bzami F, Bennani N, Amine B, Hajja-Hassouni N, Essakali M 2008 HLA polymorphism and early rheumatoid arthritis in the Moroccan population. Joint Bone Spine Sep 16 [Epub ahead of print].
Atsumi T, Amengual O, Yasuda S, Koike T 2004 Antiprothrombin antibodies-are they worth assaying? Thromb. Res. 114: 533-538. *
Atta AM, Carvalho EM, Jeronimo SM, Sousa Atta ML 2007 Serum markers of rheumatoid arthritis in visceral leishmaniasis: rheumatoid factor and anti-cyclic citrullinated peptide antibody. J. Autoimmun. 28: 55-58.
Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, Sulli A, Valesini G, Sarzi-Puttini P 2008 Infections and treatment of patients with rheumatic diseases. Clin. Exp. Rheumatol. 26: S67-S73.
Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P 2007 Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun. Rev. 6: 529-536.
Atzeni F, Doria A, Ghirardello A, Villalta D, Zampieri S, Carrabba M, Sarzi-Puttini P 2008 Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. Autoimmunity 41: 87-91.
Atzeni F, Doria A, Maurizio T, Sarzi-Puttini P 2007 What is the role of rituximab in the treatment of rheumatoid arthritis? Autoimmun. Rev. 6: 553-558.
Atzeni F, Sarzi-Puttini P 2007 Early rheumatoid arthritis. Reumatismo 59: 100-117.
Atzeni F, Sarzi-Puttini P, Deportu S, Cutolo M, Carrabba M, Straub RH 2008 In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones. Clin. Exp. Rheumatol. 26: 103-108.
Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F 2005 Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun. Rev. 4: 144-152.
Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P 2005 Autoimmunity and anti-TNF-alpha agents. Ann. N. Y. Acad. Sci. 1051: 559-569.
Auci D, Kaler L, Subramanian S, Huang Y, Frincke J, Reading C, Offner H 2007 A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells. Ann. N. Y. Acad. Sci. 1110: 630-640. *
Aud D, Peng SL 2006 Mechanisms of disease: transcription factors in inflammatory arthritis. Nat. Clin. Pract. Rheumatol. 2: 434-442. *
Audrain MA, Gourbil A, Muller JY, Esnault LM 1996 Anti-lactoferrin autoantibodies: relation between epitopes and iron-binding domain. J. Autoimmun. 9: 569-574.
Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G 2007 Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 56: 1175-1186. *
Auger I, Ragni E, Reviron D, Rossi D, Roudier J 2007 Immune response to 70 kD heat shock proteins and rheumatoid arthritis: implication of HLA-DRB1*0401. Clin. Exp. Rheumatol. 25: 933-934.
Auger I, Roudier C, Guis S, Balandraud N, Roudier J 2007 HLA-DRB1*0404 is strongly associated with anti-calpastatin antibodies in rheumatoid arthritis. Ann. Rheum. Dis. 66: 1588-1593.
Auger I, Sebbag M, Vincent C, Balandraud N, Guis S, Nogueira L, Svensson B, Cantagrel A, Serre G, Roudier J 2005 Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum. 52: 3424-3432. *
Aune TM, Maas K, Moore JH, Olsen NJ 2003 Gene expression profiles in human autoimmune disease. Curr. Pharm. Des. 9: 1905-1917.
Aune TM, Maas K, Parker J, Moore JH, Olsen NJ 2004 Profiles of gene expression in human autoimmune disease. Cell. Biochem. Biophys. 40: 81-96.
Avalos P, Camacho FM 2008 Practical management of adalimumab. Actas. Dermosifiliogr. 99 Suppl. 3: 25-27.
Aversano M, Caiazzo P, Iorio G, Ponticiello L, Lagana B, Leccese F 2005 Improvement of chronic idiopathic urticaria with L-thyroxine: a new TSH role in immune response? Allergy 60: 489-493. *
Avila-Portillo LM, Vargas-Alarcon G, Andrade F, Alarcon-Segovia D, Granados J 1994 Linkage disequilibrium of HLA-DR3 and HLA-DR4 with HLA-B alleles in Mexican patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 12: 497-502.
Avnir Y, Ulmansky R, Wasserman V, Even-Chen S, Broyer M, Barenholz Y, Naparstek Y 2007 Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. Arthritis Rheum. 58: 119-129. *
Avnon LS, Abu-Shakra M, Flusser D, Heimer D, Sion-Vardy N 2007 Pleural effusion associated with rheumatoid arthritis: what cell predominance to anticipate? Rheumatol. Int. 27: 919-925. *
Avouac J, Allanore Y 2008 Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin. Pharmacother. 9: 1121-1128.
Avouac J, Gossec L, Dougados M 2006 Diagnostic and predictive value of anti-CCP (cyclic citrullinated protein) antibodies in rheumatoid arthritis: a systematic literature review. Ann. Rheum. Dis. 65: 845-851. *
Avriel A, Zeller L, Flusser D, Abu Shakra M, Halevy S, Sukenik S 2007 Coexistence of psoriatic arthritis and systemic lupus erythematosus. Isr. Med. Assoc. J. 9: 48-49.
Awale M, Mohan CG 2008 Molecular docking guided 3D-QSAR CoMFA analysis of N-4-pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase. J. Mol. Model. 14: 937-947.
Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G 2008 CTLA-4 directly inhibits osteoclast formation. Ann. Rheum. Dis. Jan 18 [Epub ahead of print].
Aydin G, Keles I, Atalar E, Orkun S 2005 Extensive erosive arthropathy in a patient with Behcet's disease: case report. Clin. Rheumatol. 24: 645-647.
Aydinli B, Ozturk G, Balik AA, Aslan S, Erdogan F 2006 Spontaneous rupture of the spleen in secondary amyloidosis: a patient with rheumatoid arthritis. Amyloid 13: 160-163.
Aydog E, Yesilli O, Sever A, Usan H 2006 Dermatitis herpetiformis and rheumatoid arthritis. Saudi Med. J. 27: 881-884.
Ayer LM, Rubin RL, Dixon GH, Fritzler MJ 1994 Antibodies to HMG proteins in patients with drug-induced autoimmunity. Arthritis Rheum. 37: 98-103.
Azar D, Martin F 2004 Paediatric uveitis: a Sydney clinic experience. Clin. Experiment. Ophthalmol. 32: 468-471.
Azuma T, Ishimaru H, Hatta K, Kori Y 2007 Improved response to infliximab after leukocytapheresis in a patent with rheumatoid arthritis. Mod. Rheumatol. 17: 253-255. *
B'chir Hamzaoui S, Harmel A, Bouslama K, Abdallah M, Ennafaa M, M'rad S, Ben Dridi M; le groupe tunisien d'etude sur la maladie de Behcet 2006 Behcet's disease in Tunisia. Clinical study of 519 cases. Rev. Med. Interne. 27: 742-750.
Babyn P, Doria AS 2005 Radiologic investigation of rheumatic diseases. Pediatr. Clin. North Am. 52: 373-411.
Bacanli A, Sallakci N, Yavuzer U, Alpsoy E, Yegin O 2006 Toll-like receptor 2 Arg753Gln gene polymorphism in Turkish patients with Behcet's disease. Clin. Exp. Dermatol. 31: 699-701. *
Bache I, Nielsen NM, Rostgaard K, Tommerup N, Frisch M 2007 Autoimmune diseases in a Danish cohort of 4,866 carriers of constitutional structural chromosomal rearrangements. Arthritis Rheum. 56: 2402-2409. *
Bacher S, Schmitz ML 2004 The NF-kappa B pathway as a potential target for autoimmune disease therapy. Curr. Pharm. Des. 10: 2827-2837.
Bachmeyer C, Rohaut B 2006 Sarcoidosis mimicking rheumatoid arthritis. Presse. Med. 35: 623-624.
Badelon I 1999 Eye and spondylarthropathies. Rev. Prat. 49: 1995-1998.
Badsha H, Kong KO, Tak PP 2008 Rheumatoid arthritis in the United Arab Emirates. Clin. Rheumatol. 27: 739-472. *
Bae E, Kim WJ, Kang YM, Suk K, Koh EM, Cha HS, Ahn KS, Huh TL, Lee WH 2007 Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis. Clin. Exp. Immunol. 148: 410-418. *
Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L 2004 Rheumatoid arthritis and malignant lymphomas. Curr. Opin. Rheumatol. 16: 254-261.
Baecklund E, Backlin C, Iliadou A, Granath F, Ekbom A, Amini RM, Feltelius N, Enblad G, Sundstrom C, Klareskog L, Askling J, Rosenquist R 2006 Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum. 54: 3774-3781. *
Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundstrom C, Klareskog L 2006 Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54: 692-701. *
Baerwald CG, Panayi GS, Lanchbury JS 1997 Corticotropin releasing hormone promoter region polymorphisms in rheumatoid arthritis. J. Rheumatol. 24: 215-216.
Baeten D, De Keyser F, Veys EM, Theate Y, Houssiau FA, Durez P 2004 Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules. Ann. Rheum. Dis. 63: 489-493. *
Baeten D, Kruithof E, Breban M, Tak PP 2008 Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum. 58: 730-733. *
Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, Veys EM, De Keyser F 2001 Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum. 44: 2255-2262.
Baeten D, Steenbakkers PG, Rijnders AM, Boots AM, Veys EM, De Keyser F 2004 Detection of major histocompatibility complex/human cartilage gp-39 complexes in rheumatoid arthritis synovitis as a specific and independent histologic marker. Arthritis Rheum. 50: 444-451. *
Bagnato G, De Filippis LG, Caliri A, Bruno A, Gambardella N, Muscatello MR, Cambria R, Zoccali R 2006 Comparation of levels of anxiety and depression in patients with autommune and chronic-degenerative rheumatic: preliminary data. Reumatismo 58: 206-211.
Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P 2005 Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J. Rheumatol. 32: 469-476.
Baharav E, Mor F, Halpern M, Quintana F, Weinberger A 2007 Tropomyosin-induced arthritis in rats. Clin. Exp. Rheumatol. 25: S86-S92.
Baharav E, Mor F, Halpern M, Weinberger A 2004 Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J. Nutr. 134: 1964-1969. *
Bai S, Kitaura H, Zhao H, Chen J, Muller JM, Schule R, Darnay B, Novack DV, Ross FP, Teitelbaum SL 2005 FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. J. Clin. Invest. 115: 2742-2751. *
Baici A, Muntener K, Willimann A, Zwicky R 2006 Regulation of human cathepsin B by alternative mRNA splicing: homeostasis, fatal errors and cell death. Biol. Chem. 387: 1017-1021.
Baidoo L, Lichtenstein GR 2005 What next after infliximab? Am. J. Gastroenterol. 100: 80-83. *
Baier G, Asadullah K, Zugel U 2006 The immunological synapse: kinases in T cell signalling as potential drug targets. Immunol. Lett. 105: 3-5.
Baig S, Alamgir M 2008 The extrahepatic manifestations of hepatitis B virus. J. Coll. Physicians Surg. Pak. 18: 451-457.
Baillat D, Leprivier G, Regnier D, Vintonenko N, Begue A, Stehelin D, Aumercier M 2006 Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter. Oncogene 25: 5764-5776. *
Baines M, Ebringer A 1992 HLA and disease. Mol. Aspects Med. 13: 263-378.
Bajtner E, Nandakumar KS, Engstrom A, Holmdahl R 2005 Chronic development of collagen-induced arthritis is associated with arthritogenic antibodies against specific epitopes on type II collagen. Arthritis Res. Ther. 7: R1148-R1157. *
Baker DE 2004 Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev. Gastroenterol. Disord. 4: 196-210. *
Baker KP 2004 BLyS-an essential survival factor for B cells: basic biology, links to pathology and therapeutic target. Autoimmun. Rev. 3: 368-375.
Bakland G, Nordvag BY, Nossent HC 2003 Efficacy of anti-tumour necrosis factor alpha therapy with etanercept in chronic polyarthritis. Tidsskr. Nor. Laegeforen. 123: 2561-2564.
Bakland G, Nossent HC, Gran JT 2005 Incidence and prevalence of ankylosing spondylitis in Northern Norway. Arthritis Rheum. 53: 850-855. *
Balaban B, Yasar E, Ozgul A, Dincer K, Kalyon TA 2005 Sacroiliitis in familial Mediterranean fever and seronegative spondyloarthropathy: importance of differential diagnosis. Rheumatol. Int. 25: 641-644. *
Balandraud N, Gouret P, Danchin EG, Blanc M, Zinn D, Roudier J, Pontarotti P 2005 A rigorous method for multigenic families' functional annotation: the peptidyl arginine deiminase (PADs) proteins family example. BMC Genomics 6: 153. *
Balandraud N, Guis S, Baptiste Meynard J, Auger I, Roudier J, Roudier C 2007 Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 57: 762-767. *
Balandraud N, Roudier J, Roudier C 2004 Epstein-Barr virus and rheumatoid arthritis. Autoimmun. Rev. 3: 362-367.
Balbir-Gurman A, Guralnik L, Best LA, Vlodavsky E, Yigla M, Menahem Nahir A, Braun-Moscovici Y 2008 Accelerated pulmonary nodulosis and sterile pleural effusion in a patient with psoriatic arthropathy during methotrexate therapy: a case report. J. Clin. Rheumatol. Aug 1 [Epub ahead of print].
Balbir-Gurman A, Schapira D, Nahir M 2001 Arthritis related to ileal pouchitis following total proctocolectomy for ulcerative colitis. Semin. Arthritis Rheum. 30: 242-248. *
Baldassano VF Jr 1998 Ocular manifestations of rheumatic diseases. Curr. Opin. Ophthalmol. 9: 85-88.
Baldassarre ME, Altomare MA, Fanelli M, Carbone D, Di Bitonto G, Mautone A, Laforgia N 2007 Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease? Endocr. Metab. Immune Disord. Drug Targets 7: 1-5.
Baldessarini RJ 1987 Neuropharmacology of S-adenosyl-L-methionine. Am. J. Med. 83: 95-103.
Balding J, Kane D, Livingstone W, Mynett-Johnson L, Bresnihan B, Smith O, FitzGerald O 2003 Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum. 48: 1408-1413. *
Balducci-Silano PL, Layrisse ZE 1995 HLA-DP and susceptibility to insulin-dependent diabetes mellitus in an ethnically mixed population. Associations with other HLA-alleles. J. Autoimmun. 8: 425-437.
Baldys-Waligorska A, Kusnierz-Cabala B, Huszno B 2006 A special case of thyroid associated ophthalmopathy in the course of Graves-Basedow disease. Endokrynol. Pol. 57: 536-540.
Balog A, Gal J, Gyulai Z, Zsilak S, Mandi Y 2004 Tumour necrosis factor-alpha and heat-shock protein 70-2 gene polymorphisms in a family with rheumatoid arthritis. Acta Microbiol. Immunol. Hung. 51: 263-269.
Balog A, Klausz G, Gal J, Molnar T, Nagy F, Ocsovszky I, Gyulai Z, Mandi Y 2004 Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 71: 274-280.
Balsa A, Pascual-Salcedo D, Mart�n J 2007 Antibodies to citrullinated peptides in rheumathoid arthritis. Med. Clin. (Barc.) 128: 668-673.
Bamias G, Siakavellas SI, Stamatelopoulos KS, Chryssochoou E, Papamichael C, Sfikakis PP 2008 Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. Clin. Immunol. Aug 29 [Epub ahead of print].
Ban Y, Taniyama M, Tozaki T, Tomita M, Ban Y 2000 Estrogen receptor alpha dinucleotide repeat polymorphism in Japanese patients with autoimmune thyroid diseases. BMC Med. Genet. 1: 1. *
Banda NK, Takahashi K, Wood AK, Holers VM, Arend WP 2007 Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J. Immunol. 179: 4101-4109.
Banda NK, Thurman JM, Kraus D, Wood A, Carroll MC, Arend WP, Holers VM 2006 Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen-induced arthritis. J. Immunol. 177: 1904-1912. *
Bang B, Gniadecki R 2006 Severe exacerbation of psoriatic arthritis during treatment with efalizumab. A case report. Acta Derm. Venereol. 86: 456-457.
Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, Berg W, Feist E, Burmester GR 2007 Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum. 56: 2503-2511. *
Bank I, Ben-Horin S, Goldstein I, Koltakov A, Langevitz P, Ehrenfeld M, Rosenthal E, Gur H 2007 The effect of blockade of tumor necrosis factor alpha on VLA-1+T-cells in rheumatoid arthritis patients. J. Clin. Immunol. 27: 580-588. *
Bankhurst AD, Nunez SE, Draeger HT, Kettwich SC, Kettwich LG, Sibbitt WL Jr 2007 A randomized controlled trial of the reciprocating procedure device for intraarticular injection of corticosteroid. J. Rheumatol. 34: 187-192.
Banno T, Gazel A, Blumenberg M 2004 Effects of tumor necrosis factor-alpha (TNFalpha) in epidermal keratinocytes revealed using global transcriptional profiling. J. Biol. Chem. 279: 32633-32642. *
Bannwarth B 2007 Drug-induced musculoskeletal disorders. Drug Saf. 30: 27-46.
Bansback N, Brennan A, Symmons D, Nixon R, Madan J, Harrison M, Watson K 2008 Comment on: modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry: reply. Rheumatology (Oxford) 47: 1107.
Bansback N, Young A, Brennan A, Dixey J 2006 A prognostic model for functional outcome in early rheumatoid arthritis. J. Rheumatol. 33: 1503-1510.
Bansi DS, Lo S, Chapman RW, Fleming KA 1996 Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 8: 111-116.
Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P 2007 The anti-inflammatory effect of A(3) adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin. Investig. Drugs 16: 1601-1613.
Baraf HS 2007 Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Curr. Pharm. Des. 13: 2228-2236.
Baraliakos X, Listing J, Rudwaleit M, Sieper J, Braun J 2008 The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res. Ther. 10: R104. *
Barash J, Goldzweig O 2007 Possible role of streptococcal infection in flares of juvenile idiopathic arthritis. Arthritis Rheum. 57: 877-880. *
Barcellos LF, Kamdar BB, Ramsay PP, Deloa C, Lincoln RR, Caillier S, Schmidt S, Haines JL, Pericak-Vance MA, Oksenberg JR, Hauser SL 2006 Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. 5: 924-931.
Bardazzi G, Mannoni A, d'Albasio G, Bonanomi AG, Trallori G, Benucci M, Serni U, Pacini F 1997 Spondyloarthritis in patients with ulcerative colitis. Ital. J. Gastroenterol. Hepatol. 29: 520-524.
Bardin T 2004 Psoriatic rheumatism. Rev. Prat. 54: 60-68.
Baricordi OR, Govoni M, Rizzo R, Trotta F 2007 In rheumatoid arthritis, a polymorphism in the HLA-G gene concurs in the clinical response to methotrexate treatment. Ann. Rheum. Dis. 66: 1125-1126. *
Barksby HE, Lea SR, Preshaw PM, Taylor JJ 2007 The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin. Exp. Immunol. 149: 217-225. *
Barksby HE, Milner JM, Patterson AM, Peake NJ, Hui W, Robson T, Lakey R, Middleton J, Cawston TE, Richards CD, Rowan AD 2006 Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis. Arthritis Rheum. 54: 3244-3253. *
Barland P 2004 Antibodies to citrullinated peptides: current role in diagnosis, prognosis, and pathogenesis of rheumatoid arthritis. New Developments in Rheumatic Diseases 1: 6-9. *
Barnabe CC, Leclercq SA, Fitzgerald AA 2008 The development of inflammatory arthritis and other rheumatic diseases following stem cell transplantation. Semin. Arthritis Rheum. May 31 [Epub ahead of print]. *
Barnes PJ 1997 Nuclear factor-kappa B. Int. J. Biochem. Cell. Biol. 29: 867-870.
Barnes T, Moots RJ, Goodacre J 2005 Cytokine medicines in clinical practice: current issues. Cytokine 32: 62-66.
Barnetche T, Constantin A, Cantagrel A, Cambon-Thomsen A, Gourraud PA 2008 New classification of HLA-DRB1 alleles in rheumatoid arthritis susceptibility: a combined analysis of worldwide samples. Arthritis Res. Ther. 10: R26. *
Barnetche T, Constantin A, Gourraud PA, Abbal M, Garnier JG, Cantagrel A, Cambon-Thomsen A 2006 Microsatellite typing of the human leucocyte antigen region: analytical approach and contribution to rheumatoid arthritis immunogenetic studies. Tissue Antigens 68: 390-398. *
Barnstein BO, Li G, Wang Z, Kennedy S, Chalfant C, Nakajima H, Bunting KD, Ryan JJ 2006 Stat5 expression is required for IgE-mediated mast cell function. J. Immunol. 177: 3421-3426. *
Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ, Valesini G, Pitzalis C 2005 Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis Rheum. 52: 1773-1784. *
Barr C 2007 A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis. J. Infus. Nurs. 30: 96-104.
Barrera P, Balsa A, Alves H, Westhovens R, Maenaut K, Cornelis F, Fritz P, Bardin T, Ceu Maia M, Lopes-Vaz A, Pascual Salcedo D, de la Concha E, Radstake T, van de Putte LB, Migliorini P, Prudhomme JF, Charron D, Spyropoulou M, Mendes A, Spaepen M, et al 2001 Noninherited maternal antigens do not increase the susceptibility for familial rheumatoid arthritis. European Consortium on Rheumatoid Arthritis Families (ECRAF). J. Rheumatol. 28: 968-974.
Barrera P, Faure S, Prud'homme JF, Balsa A, Migliorini P, Chimenti D, Radstake TR, van de Putte LB, Pascual-Salcedo D, Westhovens R, Maenaut K, Alves H, Lopes-Vaz A, Stravopoulos C, Spyropoulou M, Fritz P, Bardin T, Charron D, Lepage V, et al 2001 European genetic study on rheumatoid arthritis: is there a linkage of the interleukin-1 (IL-1), IL-10 or IL-4 genes to RA? Clin. Exp. Rheumatol. 19: 709-714.
Barreto AM, Bigolin MC, Ramos JC, Machado LP, Silva Ldos R, Silveira RB, Boguszewski MC 2008 Growth hormone therapy for children with chronic diseases. Arq. Bras. Endocrinol. Metabol. 52: 774-782.
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, et al 2008 Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40: 955-962. *
Barrett MO, Bal BS 2007 Septic arthritis of the hip in an immune competent adult: the significance of the differential diagnosis. J. Am. Board Fam. Med. 20: 307-309.
Barrie A, Regueiro M 2007 Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 13: 1424-1429.
Barrie III AM, Plevy SE 2005 The interleukin-12 family of cytokines: therapeutic targets for inflammatory disease mediation. Clin. Appl. Immunol. Rev. 5: 225-240. *
Barsante MM, Cunha TM, Allegretti M, Cattani F, Policani F, Bizzarri C, Tafuri WL, Poole S, Cunha FQ, Bertini R, Teixeira MM 2008 Blockade of the chemokine receptor CXCR2 ameliorates adjuvant-induced arthritis in rats. Br. J. Pharmacol. 153: 992-1002. *
Bartalena L, Tanda ML, Medea A, Marcocci C, Pinchera A 2002 Novel approaches to the management of Graves' ophthalmopathy. Hormones (Athens) 1: 76-90.
Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak P, Wolbink GJ 2007 Clinical response to adalimumab: the relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66: 921-926. *
Bartfai T, Waalen J, Buxbaum JN 2007 Adipose tissue as a modulator of clinical inflammation: does obesity reduce the prevalence of rheumatoid arthritis? J. Rheumatol. 34: 488-492.
Bartke U, Venten I, Kreuter A, Gabbay S, Altmeyer P, Brockmeyer NH 2004 Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br. J. Dermatol. 150: 784-786.
Bartolozzi G, Falcini F, Volpi M, Taccetti G, Tafi L 1990 Arthropathies related to HLA-B27. Pediatr. Med. Chir. 12: 561-574.
Barton A, Bowes J, Eyre S, Spreckley K, Hinks A, John S, Worthington J 2004 A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis Rheum. 50: 1117-1121. *
Barton A, Bowes J, Eyre S, Symmons D, Worthington J, Silman A 2005 Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis. Ann. Rheum. Dis. 64: 1311-1315. *
Barton A, Eyre S, Bowes J, Ho P, John S, Worthington J 2005 Investigation of the SLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients. Arthritis Rheum. 52: 752-758. *
Barton A, Eyre S, Myerscough A, Brintnell B, Ward D, Ollier WE, Lorentzen JC, Klareskog L, Silman A, John S, Worthington J; Arthritis Rheumatism Campaign National Repository 2001 High resolution linkage and association mapping identifies a novel rheumatoid arthritis susceptibility locus homologous to one linked to two rat models of inflammatory arthritis. Hum. Mol. Genet. 10: 1901-1906. *
Barton A, Jury F, Eyre S, Bowes J, Hinks A, Ward D, Worthington J 2004 Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis. Arthritis Rheum. 50: 748-752. *
Barton A, Lamb R, Symmons D, Silman A, Thomson W, Worthington J, Donn R 2003 Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun. 4: 487